or Try an Advanced Search...

    Treatment Of Huntington's Disease Stocks List

    Symbol Grade Name % Change
    ALNY D Alnylam Pharmaceuticals, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Acute Intermittent Porphyria Alnylam Pharmaceuticals Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Antitrypsin Deficiency Beta Thalassemia Biopharmaceutical Biotechnology Cholesterol Clinical Development Deficiency Genzyme Hemoglobin Hemoglobinopathies Hemophilia Hemophilia A Huntington's Disease Hypercholesterolemia Life Sciences

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Huntington's Disease stocks.

    Symbol Grade Name Weight
    GERM C ETFMG Treatments Testing and Advancements ETF 6.15
    FBT D First Trust Amex Biotech Index Fund 3.37
    GNOM D Global X Genomics & Biotechnology ETF 3.29
    BTEC C Principal Healthcare Innovators Index ETF 3.16
    QQQN D VictoryShares Nasdaq Next 50 ETF 2.17
    View all Treatment Of Huntington's Disease ETFs...
    Compare ETFs
    Compare BTEC to QQQN Compare FBT to BTEC Compare GERM to QQQN

        Treatment Of Huntington's Disease Stocks Recent News

        Date Stock Title
        May 7 ALNY Alnylam Issues 2023 Corporate Responsibility Report
        May 5 ALNY The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts
        May 3 ALNY Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
        May 3 ALNY Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
        May 3 ALNY Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
        May 3 ALNY Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
        May 2 ALNY Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript
        May 2 ALNY Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
        May 2 ALNY Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
        May 2 ALNY Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
        May 2 ALNY Alnylam Pharmaceuticals Non-GAAP EPS of -$0.16 beats by $0.32, revenue of $494.3M beats by $67.44M
        May 2 ALNY Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
        May 1 ALNY Alnylam Pharmaceuticals Q1 2024 Earnings Preview
        Related Industries: Biotechnology
        Related Stock Lists: Acute Intermittent Porphyria Alnylam Pharmaceuticals Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Antitrypsin Deficiency Beta Thalassemia Biopharmaceutical Biotechnology Cholesterol Clinical Development Deficiency Genzyme Hemoglobin Hemoglobinopathies Hemophilia Hemophilia A Huntington's Disease Hypercholesterolemia Life Sciences
        Treatment Of Huntington's Disease

        Browse All Tags